The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 747
Zanoni, P., Velagapudi, S., Yalçınkaya, M., Rohrer, L., & von Eckardstein, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.881 · Cited by 97
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 99
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 99
Self-citationGeorgakis, M. K., Malik, R., Anderson, C. D., Parhofer, K. G., Hopewell, J. C., & Dichgans, M. (2019) · Brain · doi:10.1093/brain/awz413 · Cited by 91
Karagiannis, A. D., Liu, M., Toth, P. P., Zhao, S., Agrawal, D. K., Libby, P., & Chatzizisis, Y. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0718-x · Cited by 93
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni‐Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 91
When Will Mendelian Randomization Become Relevant for Clinical Practice and Public Health?
Davey Smith, G., Paternoster, L., & Relton, C. (2017) · JAMA · doi:10.1001/jama.2016.21189 · Cited by 87
Kent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
Handelsman, Y., & Lepor, N. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008953 · Cited by 88
Ruscica, M., Ferri, N., Fogacci, F., Rosticci, M., Botta, M., Marchianò, S., Magni, P., D’Addato, S., Giovannini, M., Borghi, C., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005764 · Cited by 85
Ballantyne, C. M., Ditmarsch, M., Kastelein, J. J. P., Nelson, A. J., Kling, D. F., Hsieh, A., Curcio, D. L., Maki, K. C., Davidson, M. H., & Nicholls, S. J. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.05.098 · Cited by 84
Richardson, T. G., Hemani, G., Gaunt, T. R., Relton, C. L., & Smith, G. D. (2020) · Nature Communications · doi:10.1038/s41467-019-13921-9 · Cited by 84
Zheng, J., Brion, M., Kemp, J. P., Warrington, N. M., Borges, M. C., Hemani, G., Richardson, T. G., Rasheed, H., Qiao, Z., Haycock, P., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3989 · Cited by 82
Cupido, A. J., Asselbergs, F. W., Natarajan, P., CHARGE Inflammation Working Group, Ridker, P. M., Hovingh, G. K., & Schmidt, A. F. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15191 · Cited by 81
Genetic insights into therapeutic targets for aortic aneurysms: A Mendelian randomization study
Chen, Y., Xu, X. P., Wang, L., Li, K., Sun, Y., Xiao, L., Dai, J., Huang, M., Wang, Y., & Wang, D. W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104199 · Cited by 82
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans
Baragetti, A., Balzarotti, G., Grigore, L., Pellegatta, F., Guerrini, U., Pisano, G., Fracanzani, A. L., Fargion, S. R., Norata, G. D., & Catapano, A. L. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317724342 · Cited by 80
Self-citationLotta, L. A., Stewart, I. D., Sharp, S. J., Day, F. R., Burgess, S., Luan, J., Bowker, N., Cai, L., Li, C., Wittemans, L. B. L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2866 · Cited by 72
Shu, L., Chan, K. H. K., Zhang, G., Huan, T., Kurt, Z., Zhao, Y., Codoni, V., Trégouët, D., Yang, J. J., Wilson, J. G., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007040 · Cited by 81
DOMANSKI, M. J., Wu, C. O., Tian, X., Hasan, A., Ma, X., Huang, Y., Miao, R., Reis, J. P., Bae, S., Husain, A., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.024 · Cited by 78
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
Hopewell, J. C., Malik, R., Valdés‐Márquez, E., Worrall, B. B., & Collins, R. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx373 · Cited by 77
Macchi, C., Banach, M., Corsini, A., Sirtori, C., Ferri, N., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319831500 · Cited by 78
Enas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.04.007 · Cited by 76
Masana, L., Girona, J., Ibarretxe, D., Rodríguez‐Calvo, R., Rosales, R., Vallvé, J.-C., Rodríguez-Borjabad, C., Guardiola, M., Rodríguez, M. M., Guaita‐Esteruelas, S., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.018 · Cited by 71
Relative effects of LDL-C on ischemic stroke and coronary disease
Valdés‐Márquez, E., Parish, S., Clarke, R., Stari, T., Worrall, B. B., & Hopewell, J. C. (2019) · Neurology · doi:10.1212/wnl.0000000000007091 · Cited by 71
Yarmolinsky, J., Díez‐Obrero, V., Richardson, T. G., Pigeyre, M., Sjaarda, J., Paré, G., Walker, V. M., Vincent, E. E., Tan, V. Y., Obón‐Santacana, M., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003897 · Cited by 71
Genetic Insights for Drug Development in NAFLD
Eslam, M., & George, J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.05.002 · Cited by 68
Nelson, A. J., Sniderman, A. D., Ditmarsch, M., Dicklin, M. R., Nicholls, S. J., Davidson, M. H., & Kastelein, J. J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169417 · Cited by 72
Diabetogenic Action of Statins: Mechanisms
Carmena, R., & Betteridge, D. J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0780-z · Cited by 74
Cupido, A. J., Reeskamp, L. F., Hingorani, A. D., Finan, C., Asselbergs, F. W., Hovingh, G. K., & Schmidt, A. F. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2333 · Cited by 68
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 70
Leiter, L. A., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Mancini, G. B. J., Ray, K. K., Hanselman, J. C., Ye, Z., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14645 · Cited by 69
Self-citationBempedoic acid: effects on lipoprotein metabolism and atherosclerosis
Burke, A. C., Telford, D. E., & Huff, M. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000565 · Cited by 67
Lipid lowering agents of natural origin: An account of some promising chemotypes
Singh, S. P., & Sashidhara, K. V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.020 · Cited by 67
Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Limongelli, G., Pirro, M., & Calabrò, P. (2020) · BioFactors · doi:10.1002/biof.1619 · Cited by 68
Disrupting upstream translation in mRNAs is associated with human disease
Lee, D. S. M., Park, J., Kromer, A., Baras, A., Rader, D. J., Ritchie, M. D., Ghanem, L. R., & Barash, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-21812-1 · Cited by 70
Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes
Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M., Feldreich, T., Sundström, J., Carrero, J. J., Leppert, J., Hedberg, P., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4641-z · Cited by 65
Momtazi‐Borojeni, A. A., Jaafari, M. R., Badiee, A., Banach, M., & Sahebkar, A. (2019) · BMC Medicine · doi:10.1186/s12916-019-1457-8 · Cited by 66
RetractedInterpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies
Ference, B. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.06.007 · Cited by 65
Self-citationLipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 67
Koh, K. K., Nam, C., Chao, T., Liu, M.-E., Wu, C.-J., Kim, D., Kim, C. J., Li, I., Li, J., Baccara‐Dinet, M. T., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.007 · Cited by 61
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 65
Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis
Chen, L., Qiu, W., Sun, X., Gao, M., Zhao, Y., Li, M., Fan, Z., & Lv, G. (2023) · Gut · doi:10.1136/gutjnl-2023-330784 · Cited by 65
New Pharmacological Approaches to Target PCSK9
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00847-7 · Cited by 63
Self-citationMarcovina, S. M., Viney, N. J., Hughes, S. G., Xia, S., Witztum, J. L., & Tsimikas, S. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.024 · Cited by 61
Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61
Richardson, T. G., Wang, Q., Sanderson, E. C. M., Mahajan, A., McCarthy, M. I., Frayling, T. M., Ala‐Korpela, M., Sniderman, A. D., Smith, G. D., & Holmes, M. V. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00086-6 · Cited by 61
Liu, J., Cheng, Y., Li, M., Zhang, Z., Li, T., & Luo, X. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01456-5 · Cited by 60
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 60
Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
Masson, W. M., Lobo, M., Siniawski, D. A., Huerin, M. S., Molinero, G., Valéro, R., & Nogueira, J. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.005 · Cited by 60
Kim, J., Lee, H. S., & Lee, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0799-4 · Cited by 61
Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60
Hovingh, G. K., Raal, F. J., Dent, R. E., Stefanutti, C., Descamps, O. S., Masana, L., Lira, A., Bridges, I. M., Coll, B., & SULLIVAN, D. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.003 · Cited by 61
Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study
Ferri, N., Ruscica, M., Coggi, D., Bonomi, A., Amato, M., Frigerio, B., Sansaro, D., Ravani, A. L., Veglia, F., Capra, N., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.014 · Cited by 60
Yang, S., Xu, R., Cui, C.-J., Wang, Y., Du, Y., Chen, Z., Yao, Y., Ma, C., Zhu, C., Guo, Y., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0689-9 · Cited by 58
Hindy, G., Åkesson, K., Melander, O., Aragam, K. G., Haas, M. E., Nilsson, P. M., Kadam, U. T., & Orho‐Melander, M. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40812 · Cited by 59
Fang, S., Yarmolinsky, J., Gill, D., Bull, C. J., Perks, C. M., the PRACTICAL Consortium, Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1003988 · Cited by 55
“by previous MR studies, for therapies such as statins (which target HMG-CoA reductase (HMGCR)), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and Ezetimibe (which targets Niemann–Pick C1-Like 1 (NPC1L1)) [20,21].”
MethodMendelian randomization in pharmacogenomics: The unforeseen potentials
Khasawneh, L. Q., Al-Mahayri, Z. N., & Ali, B. R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112952 · Cited by 54
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 62
Gong, Y., Ma, Y., Ye, Z., Fu, Z., Yang, P., Gao, B., Guo, W., Hu, D., Ye, J., Ma, S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.07.006 · Cited by 54
Walley, K. R., Boyd, J. H., Kong, H. J., & Russell, J. A. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003551 · Cited by 54
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia
Zhao, Z., Du, S., Shen, S., Luo, P., Ding, S., Wang, G., & Wang, L. (2019) · Medicine · doi:10.1097/md.0000000000014400 · Cited by 55
Ala‐Korpela, M. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz068 · Cited by 54
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 58
Evolocumab and clinical outcomes in patients with cardiovascular disease
Hadjiphilippou, S., & Ray, K. K. (2017) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2017.212 · Cited by 52
The Reciprocal Relationship between LDL Metabolism and Type 2 Diabetes Mellitus
Bonilha, I., Hajduch, É., Luchiari, B., Nadruz, W., Goff, W. L., & Sposito, A. C. (2021) · Metabolites · doi:10.3390/metabo11120807 · Cited by 58
A robust cis-Mendelian randomization method with application to drug target discovery
Lin, Z., & Pan, W. (2024) · Nature Communications · doi:10.1038/s41467-024-50385-y · Cited by 57
Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality
Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.517 · Cited by 51
Transcriptome‐wide association studies: a view from Mendelian randomization
Zhu, H., & Zhou, X. (2020) · Quantitative Biology · doi:10.1007/s40484-020-0207-4 · Cited by 55
Caselli, C., Turco, S. D., Ragusa, R., Lorenzoni, V., Graaf, M. A. D., Basta, G., Scholte, A. J. H. A., Caterina, R. D., & Neglia, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0949-3 · Cited by 50
Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study
Thomas, D. G., Wei, Y., & Tall, A. R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p120001000 · Cited by 53
PCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions
Guo, Y., Daghlas, I., Gormley, P., Giulianini, F., Ridker, P. M., Mora, S., Kurth, T., Rist, P. M., & Chasman, D. I. (2021) · Neurology · doi:10.1212/wnl.0000000000012919 · Cited by 48
Patti, G., Spinoni, E. G., Grisafi, L., Mehran, R., & Mennuni, M. G. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac049 · Cited by 52
Margerie, D., Lefèbvre, P., Raverdy, V., Schwahn, U., Ruetten, H., Larsen, P. J., Duhamel, A., Labreuche, J., Thuillier, D., Derudas, B., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0536-1 · Cited by 48
Evolocumab in Patients with Cardiovascular Disease
Koskinas, K. C., & Windecker, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1708587 · Cited by 47
Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study
Thakral, A., Lee, J. W., Hou, T., Hueniken, K., Dudding, T., Gormley, M., Virani, S., Olshan, A. F., Diergaarde, B. B., Ness, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51679-x · Cited by 53
Wu, Z., Huang, Z., Lichtenstein, A. H., Liu, Y., Chen, S., Jin, Y., Na, M., Bao, L., Wu, S., & Gao, X. (2021) · BMC Medicine · doi:10.1186/s12916-021-02014-4 · Cited by 46
Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
Spolitu, S., Dai, W., Zadroga, J. A., & Özcan, L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000601 · Cited by 51
Walker, V. M., Zheng, J., Gaunt, T. R., & Smith, G. D. (2022) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122120-024910 · Cited by 44
Feng, Q., Wei, W., Chung, C. P., Levinson, R. T., Sundermann, A. C., Mosley, J. D., Bastarache, L. A., Ferguson, J. F., Cox, N. J., Roden, D. M., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002642 · Cited by 44
Yalçınkaya, M., Kerksiek, A., Gebert, K., Annema, W., Sibler, R., Radosavljevic, S., Lütjohann, D., Rohrer, L., & von Eckardstein, A. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000509 · Cited by 45
Luo, S., Schooling, C. M., Wong, I. C. K., & Yeung, S. L. A. (2020) · Diabetologia · doi:10.1007/s00125-020-05243-z · Cited by 45
Mbikay, M., Mayne, J., Sirois, F., Fedoryak, O. D., Raymond, A., Noad, J., & Chrétien, M. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700729 · Cited by 45
Genga, K. R., Lo, C., Cirstea, M. S., Filho, F. S. L., Walley, K. R., Russell, J. A., Linder, A., Francis, G. A., & Boyd, J. H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.032 · Cited by 46
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
PCSK9: from biology to clinical applications
Blanchard, V., Khantalin, I., Ramin‐Mangata, S., Chemello, K., Nativel, B., & Lambert, G. C. (2018) · Pathology · doi:10.1016/j.pathol.2018.10.012 · Cited by 47
Turgeon, R. D., Tsuyuki, R. T., Gyenes, G. T., & Pearson, G. J. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.04.002 · Cited by 43
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Schmidt, A. F., Holmes, M. V., Preiss, D., Swerdlow, D. I., Denaxas, S., Fatemifar, G., Faraway, R., Finan, C., Lumbers, R. T., Henry, A., et al. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1187-z · Cited by 41
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 46
Nelson, C. P., Lai, F. Y., Nath, M., Ye, S., Webb, T. R., Schunkert, H., & Samani, N. J. (2019) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002196 · Cited by 55
Sattar, N. A., Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. M., & Preiss, D. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.047 · Cited by 40
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Human Genomics and Drug DevelopmentPreprint
Schmidt, A. F., Hingorani, A. D., & Finan, C. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039230 · Cited by 40
Schwartz, G. G., Szarek, M. J., Bittner, V., Bhatt, D. L., Díaz, R., Goodman, S. G., Jukema, J. W., Loy, M., Manvelian, G. Z., Pordy, R. C., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2842 · Cited by 40
Pirillo, A., Catapano, A. L., & Norata, G. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00972-x · Cited by 41
Self-citationEffects of different weight loss approaches on CVD risk
Clifton, P. M., & Keogh, J. B. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0728-8 · Cited by 36
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
Carugo, S., Sirtori, C. R., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01074-y · Cited by 40
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
Zheng-Lin, B., & Ortíz, A. (2018) · Drugs · doi:10.1007/s40265-017-0858-2 · Cited by 40
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
